文献速递类风湿关节炎其他结缔组织病

甲氨蝶呤的使用降低类风湿关节炎患者的死亡风险:队列研究的系统评价与荟萃分析

Methotrexate use reduces mortality risk in rheumatoid arthritis: A systematic review and meta-analysis of cohort studies.
PubMed 文献 · Semin Arthritis Rheum · 2022-05-30

该系统评价与荟萃分析纳入15项队列研究,评估甲氨蝶呤(MTX)对类风湿关节炎(RA)患者死亡风险的影响。结果显示,MTX显著降低RA患者全因死亡率(HR=0.59,95%CI 0.50-0.71,P<0.001),且与RA合并心血管疾病所致死亡率(HR=0.72,95%CI 0.53-0.97,P=0.031)及RA相关间质性肺病所致死亡率(HR=0.44,95%CI 0.20-0.95,P=0.037)降低独立相关。

要点

  • MTX显著降低RA患者全因死亡率(HR=0.59,95%CI 0.50-0.71,P<0.001)。
  • MTX与RA合并心血管疾病所致死亡率降低独立相关(HR=0.72,95%CI 0.53-0.97,P=0.031)。
  • MTX显著降低RA相关间质性肺病所致死亡率(HR=0.44,95%CI 0.20-0.95,P=0.037)。

核心结论

  • MTX可显著降低RA患者的全因死亡率,并具体降低RA合并心血管疾病及RA相关间质性肺病所致死亡率。

研究设计与样本

  • 系统评价与荟萃分析,最终纳入15项队列研究,汇总全因死亡率的风险比(HR),并分别汇总RA合并心血管疾病(RA-CVD)及RA相关间质性肺病(RA-ILD)所致死亡率的HR进行分析。

主要发现

  • 15项研究数据的荟萃分析显示,MTX显著降低RA患者全因死亡率(HR=0.59,95%CI 0.50-0.71,P<0.001)。
  • MTX与RA-CVD所致死亡率降低独立相关(HR=0.72,95%CI 0.53-0.97,P=0.031)。
  • MTX亦显著降低RA-ILD所致死亡率(HR=0.44,95%CI 0.20-0.95,P=0.037)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis(RA) sufferers have a higher mortality risk than the healthy population, and methotrexate (MTX) as a base drug for RA treatment is believed to affect patients mortality. Systematic analyses of MTX and RA mortality are lacking and it is still confused about the role of MTX on the long-term prognosis of RA. METHODS: We performed a systematic review and meta-analysis to identify any influence of MTX on mortality among RA patients. Hazard ratio(HR) for all-cause mortality were pooled in a meta-analysis, and HR for mortality from RA with cardiovascular diseases (RA-CVD) and mortality from RA associated interstitial lung diseases (RA-ILD) were also pooled and analyzed. RESULTS: Fifteen studies were eventually included. Meta-analysis of data from 15 studies on overall mortality showed that MTX significantly reduced mortality in patients with RA (HR = 0.59, 95%CI 0.50-0.71, P < 0.001), MTX was independently associated with decreased RA-CVD-induced mortality (HR = 0.72, 95%CI 0.53-0.97, P = 0.031). In the meanwhile, MTX was also significantly reduced mortality in RA-ILD (HR = 0.44, 95%CI 0.20-0.95, P = 0.037). CONCLUSION: MTX can significantly decrease the overall mortality for RA patients, specifically, RA-CVD- and RA-ILD-induced mortality were reduced.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Xu J, Xiao L, Zhu J, et al. Methotrexate use reduces mortality risk in rheumatoid arthritis: A systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2022. PMID: 35671648. doi:10.1016/j.semarthrit.2022.152031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。